Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.

Nilotinib and imatinib are tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). In vitro, imatinib and nilotinib inhibit osteoclastogenesis, and in patients they reduce levels of bone resorption. One of the mechanisms t...

Full description

Bibliographic Details
Main Authors: Susannah O'Sullivan, Mei Lin Tay, Jian-Ming Lin, Usha Bava, Karen Callon, Jillian Cornish, Dorit Naot, Andrew Grey
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5063333?pdf=render

Internet

http://europepmc.org/articles/PMC5063333?pdf=render

Similar Items